Doxorubicin-melphalan with and without cisplatin in advanced ovarian cancer--ten-year survival results from a prospective randomized study by the Swedish Cooperative Ovarian Cancer Study Group.

In a controlled prospective randomized study the regimen doxorubicin (A) 40 mg/m2 + melphalan (M) 0.4 mg/kg was compared with A + M + cisplatin (C) 50 mg/m2 given every four weeks in advanced ovarian cancer, FIGO stage III or IV and with serous or anaplastic histology. From 1981 to 1983, 300 patients entered the study and 295 patients were evaluable for response, toxicity and long-term survival.

Clear cell adenocarcinoma of the urethra. A case report.

Clear cell adenocarcinoma of the urethra is a very rare entity. The presented case in a 35-year-old woman is the fourth in the literature. The tumour was localized in the wall of the urethra and infiltrated into the outer muscular layer of the urinary bladder.